Mengjiao Zhou

ORCID: 0000-0003-0899-9229
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Nanoplatforms for cancer theranostics
  • Nanoparticle-Based Drug Delivery
  • Luminescence and Fluorescent Materials
  • Salivary Gland Tumors Diagnosis and Treatment
  • Graphene and Nanomaterials Applications
  • Structural Engineering and Vibration Analysis
  • Advanced Nanomaterials in Catalysis
  • Vibration Control and Rheological Fluids
  • RNA Interference and Gene Delivery
  • Reconstructive Surgery and Microvascular Techniques
  • Ear and Head Tumors
  • Smart Materials for Construction
  • Supercapacitor Materials and Fabrication
  • Cancer-related molecular mechanisms research
  • Advanced biosensing and bioanalysis techniques
  • RNA modifications and cancer
  • Microbial Fuel Cells and Bioremediation
  • Animal Virus Infections Studies
  • Electrochemical sensors and biosensors
  • Microstructure and Mechanical Properties of Steels
  • Photodynamic Therapy Research Studies
  • Ultrasound and Hyperthermia Applications
  • Extracellular vesicles in disease
  • Surface Treatment and Residual Stress
  • Tracheal and airway disorders

Nantong University
2019-2025

Tianjin University of Traditional Chinese Medicine
2025

Zhengzhou University
2018-2024

Jiangsu University
2024

Chongqing University
2024

Beijing Tongren Hospital
2018-2023

Capital Medical University
2018-2023

Chinese Academy of Medical Sciences & Peking Union Medical College
2022-2023

First Affiliated Hospital of Zhengzhou University
2023

Hubei Polytechnic University
2023

Considering the obvious advantages in efficacy and price, doxorubicin (DOX) has been widely used for a range of cancers, which is usually encapsulated various nanocarriers drug delivery. Although effective, most nanocarrier-based delivery systems, loading capacity DOX rather low; this can lead to undesired systemic toxicity excretion concern. Herein, we report first time usage pure nanoparticles (DOX NPs) without addition any carriers enhanced chemotherapy against drug-resistance. The...

10.1039/c5nr00290g article EN Nanoscale 2015-01-01

Lonidamine (LND) can act on mitochondria and inhibit energy metabolism in cancer cells therefore has been used together with chemotherapy drugs for synergistically enhanced therapeutic efficacy. However, its use is hindered by the poor solubility slow diffusion cytoplasm. To address these problems, we designed prepared aqueous dispersible nanoparticles (NPs) containing integrated components including triphenylphosphine (TPP) to target of LND doxorubicin (DOX) synergistic treatment conquering...

10.1021/acsami.7b14577 article EN ACS Applied Materials & Interfaces 2017-11-24

Nanoscale size controllable and surface modifiable zeolitic imidazolate framework-8–poly(acrylic acid sodium salt) (ZIF-8–PAAS) nanocomposites are fabricated by employing PAAS nanospheres as a soft template. These ZIF-8–PAAS have different sizes ranging from 30 to 200 nm exhibit crystallinity, pH sensitivity. can be employed vectors deliver doxorubicin for anticancer therapy, leading greatly enhanced drug therapeutic efficacy when tested in cell lines mice model. Systematic toxicity...

10.1021/acsami.7b10064 article EN ACS Applied Materials & Interfaces 2017-09-06

Hybrid nanostructures with combined functionalities can be rationally designed to achieve synergistic effects for efficient cancer treatment. Herein, a multifunctional nanoplatform is constructed, containing an inner core of anticancer drug MTX surrounding by nanometer-thin layer gold as the shell Fe3O4 magnetic nanoparticles (NPs) evenly distributed in layer, and outermost hybrid LA-PEG-MTX molecules surface coating agent (denoted MFG-LPM NPs). This nanocomposite possesses very high loading...

10.1021/acsami.6b16486 article EN ACS Applied Materials & Interfaces 2017-03-06

Pancreatic cancer is a malignant disease with high mortality, and its systemic treatment strategy mainly focuses on chemotherapy. Yet, the overall prognosis of pancreatic patients still extremely poor low survival rate. Gemcitabine (GEM) widely used chemotherapeutic agent for cancer. However, GEM chemoresistance remains major challenge. In this study, we prepared calcium carbonate nanoparticles (CaCO3 NPs) loaded nucleotide reductase inhibitor (Triapine) to suppress resistance cells...

10.1016/j.ijpharm.2023.122844 article EN cc-by-nc-nd International Journal of Pharmaceutics 2023-03-14

Mesenchymal stem cells (MSCs) have shown great potential in the treatment of several inflammatory diseases due to their immunomodulatory ability, which is mediated by exosomes secreted MSCs (MSC-Exs). The incidence bowel disease (IBD) increasing globally, but there currently no long-term effective treatment. As an emerging therapy, MSC-Exs proven be alleviating IBD experimentally, and specific mechanism continues explored. gut microbiota plays important role occurrence development IBD, can...

10.3390/ph17050607 article EN cc-by Pharmaceuticals 2024-05-09

Layered double hydroxide (LDH) nanoparticles have been widely used for various biomedical applications. However, because of the difficulty surface functionalization LDH nanoparticles, systemic administration these nanomaterials in vivo therapy remains a bottleneck. In this work, we develop novel type aqueous dispersible two-dimensional ultrathin nanosheets with size about 50 nm and thickness 1.4 to 4 nm. We are able covalently attach positively charged rhodamine B fluorescent molecules...

10.1021/acsami.7b05294 article EN ACS Applied Materials & Interfaces 2017-09-15

Many drug molecules can be directly used as nanomedicine without the requirement of any inorganic or organic carriers such silica and liposome nanostructures. This new type carrier-free nanoparticles (NPs) has great potential in clinical treatment because its ultra-high loading capacity biodegradability. For practical applications, it is essential for to possess robust stability minimal premature release therapeutic during circulation blood stream. To meet this requirement, herein, we...

10.1039/c5nr09167e article EN cc-by Nanoscale 2016-01-01
Coming Soon ...